Spinal cord injury (SCI) is a debilitating condition, which leads to a permanent loss of functions below the injury site. The events which take place after SCI are characterized by cellular death, release of inhibitory factors, and inflammation. Many therapies have been studied to cure SCI, among them magnetic stimulation aims to reduce the secondary damages in particular by decreasing apoptosis, while, cellular transplantation promotes neuroregeneration by enhancing axonal regrowth. In the present study, we compared individually primary olfactory ensheathing cell (OEC) transplantation and repetitive trans-spinal magnetic stimulation (rTSMS) and then, we combined these two therapeutic approaches on tissue repair and functional recovery after SCI. To do so, SCIs were performed at Th10 level on female C57BL/6 mice, which were randomized into four groups: SCI, SCI + primary bOECs, SCI + STM, SCI + primary bulbar olfactory ensheathing cells (bOECs) + stimulation (STM). On these animals bioluminescence, immunohistological, and behavioral experiments were performed after SCI. Our results show that rTSMS has beneficial effect on the modulation of spinal scar by reducing fibrosis, demyelination, and microglial cell activation and by increasing the astroglial component of the scar, while, primary bOEC transplantation decreases microglial reactivity. At the opposite, locotronic experiments show that both treatments induce functional recovery. We did not observed any additional effect by combining the two therapeutic approaches. Taken together, the present study indicates that primary bOEC transplantation and rTSMS treatment act through different mechanisms after SCI to induce functional recovery. In our experimental paradigm, the combination of the two therapies does not induce any additional benefit.
Keywords: RRID:AB_10563302: PDGFRβ, Abcam, ab91066; RRID:AB_10643424: PE, poly4064, BioLegend, 406408; RRID:AB_2313568: Jackson ImmunoResearch, 711-166-152; RRID:AB_2340667: Jackson ImmunoResearch, 712-165-153; RRID:AB_2340812: Jackson ImmunoResearch, 715-165-140; RRID:AB_2715913: Alexa 488, MRG2b-85, BioLegend; RRID:AB_306827: p75, Abcam, ab8874; RRID:AB_476889: GFAP Cy3-conjugated Sigma-Aldrich, C9205; RRID:AB_777165:P DGFRβAbcam ab32570; RRID:AB_839504: Iba1, Wako, 019-19741; RRID:AB_94975: MBP, Millipore, MAB386; RRID:IMSR_JAX:008450: L2G85Chco+/+ (FVB-Tg(CAG-luc,-GFP)L2G85Chco/J); glial scar; magnetic stimulation; olfactory ensheathing cells and neuroregeneration; rehabilitation; spinal cord injury.
© 2021 The Authors. Journal of Neuroscience Research published by Wiley Periodicals LLC.